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Introduction
Although Portugal was one of the first countries eradicat-
ing malaria in Europe, the burden of the disease remains
high, particularly due to the close relationship with its
former african colonies. Due to its adverse effects and
higher mortality rate in patients treated with quinine,
methanalysis by the Cochrane Group published in June
2012, suggests artesunate as first line therapy in both
children and adults with severe malaria, particularly cere-
bral malaria.
Objectives
To investigate the clinical impact as well as the efficacy
and adverse effects of quinine based regimes in the treat-
ment of malaria.
Methods
We did a retrospective, observational study reviewing the
files of all admitted patients between 2009 and 2015 in our
specialised Infectious Diseases ICU. We selected all cases
with confirmed infections by P. falciparum, and registered
parameters like age, gender, nationality, country of trans-
mission, severe malaria criteria, indications and contrain-
dications of intravenous quinine, as well as its adverse
effects and clinical outcome.
Results
A total of 24 patients were included in the study, 18 (75%)
males, all adults with an average age of 41,3 ± 13,3 years.
We consider that 15 (62,5%) patients had developed partial
immunity as considered in persons living in an endemic
area for more than six months. All cases were imported
from endemic countries in Africa. No patients underwent
prophylaxis for malaria. The mean time between onset of
the symptoms and hospital admission was 4,3 ± 2,2 days.
Parasitemia, quantified in all but 2 patients, was, on aver-
age, 18,5% ± 15,2 (from 2 to 60%), wherein 18 (81,8%)
patients developed parasitemia greater than 5%. Severe
malaria, as defined by the WHO, was observed in 22
(91,7%) of the patients, 15 of whom (68,2%) had 4 or more
criteria. The mean Apache II score at admission was 16,8
± 7,7 (from 1 to 33) and the SOFA score was 11,4 ± 6,1
(from 4 to 24), either without correlation with the
observed intra-hospitalar mortality rate (8,3%; n = 2).
Overall, 20 (83,3%) of the patients were treated with intra-
venous quinine, being the loading dose between 750 and
1750mg. The mean time between the onset of therapeutic
and parasitemia < 1% was 2,3 ± 1,2 days (from 0,25 to 4).
The most common adverse effects of quinine, besides the
expectable cinchonism, was mild hypoglycaemia (50%;
n = 12). Three (12,5%) patients needed aminergic support
after initiating quinine. Also 3 patients (12,5%) developed
non-severe arrhythmia.
Conclusions
Although the study is small in size, it confirms the efficacy
and reasonable tolerability of quinine based regimes, as
opposite to what is described with quinidine that is more
cardiotoxic. As so, the true role of artesunate in an experi-
enced and well equipped intensive care unit remains
obscure. Attending to the risk of late haemolytic anaemia,
its use should be subject of further benefit/risk studies
especially in cases of cerebral malaria and for extremely
high parasitemia.
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